Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

SUSPENDED

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2003-08-31

Study Completion Date

2004-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the biological activity of ZD6126 in subjects with newly diagnosed metastatic renal cell carcinoma (stage IV).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma

NCT00625768

Metastatic Renal Cell Carcinoma Metastatic Malignant Melanoma

COMPLETED PHASE1

AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer

NCT00303862

Clear Cell Renal Cell Carcinoma Recurrent Renal Cell Cancer Stage IV Renal Cell Cancer

TERMINATED PHASE2

MEDI4736 Combinations in Metastatic Renal Cell Carcinoma

NCT02819596

Renal Clear Cell Carcinoma Renal Papillary Cell Carcinoma

COMPLETED PHASE2

Decitabine in Treating Patients With Melanoma or Other Advanced Cancer

NCT00002980

Chronic Myeloproliferative Disorders Leukemia Lymphoma +4 more

COMPLETED PHASE1

Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer

NCT00604721

Adult Primary Hepatocellular Carcinoma Advanced Adult Primary Liver Cancer Localized Unresectable Adult Primary Liver Cancer +1 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Renal Cell Kidney Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ZD6126

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Newly diagnosed metastatic renal cell carcinoma
* Suitable for nephrectomy

Exclusion Criteria

* Prior chemotherapy, biological therapy or radiation therapy for renal cell carcinoma or within the last 3 years for any other cancer
* Significant cardiac event within 3 months of entry
* Any history of coronary angioplasty or history of myocardial infarction

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No